• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    12 Health Care Stocks Moving In Thursday's After-Market Session

    10/12/23 5:31:54 PM ET
    $BLPH
    $BPTH
    $BYSI
    $CMRA
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $BLPH alert in real time by email

    Gainers

    • Bio-Path Hldgs (NASDAQ:BPTH) stock increased by 158.8% to $1.02 during Thursday's after-market session. Today's trading volume for this security ended up closing at 18.9 million shares, which is 5623.9 percent of its average volume over the last 100 days. The market value of their outstanding shares is at $11.6 million.
    • Comera Life Sciences (NASDAQ:CMRA) shares increased by 63.0% to $0.52. At the close, Comera Life Sciences's trading volume reached 572.6K shares. This is 1127.9% of its average volume over the last 100 days. The market value of their outstanding shares is at $15.9 million.
    • Scinai Immunotherapeutics (NASDAQ:SCNI) stock rose 17.02% to $0.77. The company's market cap stands at $3.6 million.
    • 60 Degrees (NASDAQ:SXTP) stock moved upwards by 16.69% to $0.82. The company's market cap stands at $4.7 million.
    • Bellerophon Therapeutics (NASDAQ:BLPH) shares increased by 13.35% to $0.45. The company's market cap stands at $5.5 million.
    • Relay Therapeutics (NASDAQ:RLAY) stock moved upwards by 12.01% to $8.86. Today's trading volume for this security ended up closing at 175.8K shares, which is 18.0 percent of its average volume over the last 100 days. The market value of their outstanding shares is at $1.0 billion.

    Losers

    • Cassava Sciences (NASDAQ:SAVA) stock decreased by 44.2% to $9.79 during Thursday's after-market session. This security traded at a volume of 761.8K shares come close, making up 92.6% of its average volume over the last 100 days. The company's market cap stands at $410.8 million.
    • Outset Medical (NASDAQ:OM) stock decreased by 33.24% to $4.52. This security traded at a volume of 421.5K shares come close, making up 66.4% of its average volume over the last 100 days. The company's market cap stands at $225.0 million.
    • T2 Biosystems (NASDAQ:TTOO) stock decreased by 29.66% to $0.12. Today's trading volume for this security ended up closing at 84.9 million shares, which is 77.0 percent of its average volume over the last 100 days. The company's market cap stands at $40.8 million.
    • OpGen (NASDAQ:OPGN) stock decreased by 21.74% to $0.72. Today's trading volume for this security ended up closing at 21.0 million shares, which is 937.9 percent of its average volume over the last 100 days. The market value of their outstanding shares is at $6.4 million.
    • Tempest Therapeutics (NASDAQ:TPST) shares decreased by 14.33% to $3.41. At the close, Tempest Therapeutics's trading volume reached 8.0 million shares. This is 251.6% of its average volume over the last 100 days. The market value of their outstanding shares is at $45.4 million.
    • BeyondSpring (NASDAQ:BYSI) shares declined by 13.98% to $0.92. The market value of their outstanding shares is at $35.8 million. See Also: www.benzinga.com/money/best-healthcare-stocks/

    This article was generated by Benzinga's automated content engine and reviewed by an editor.

    Get the next $BLPH alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $BLPH
    $BPTH
    $BYSI
    $CMRA

    CompanyDatePrice TargetRatingAnalyst
    Relay Therapeutics Inc.
    $RLAY
    1/26/2026$14.00Perform → Outperform
    Oppenheimer
    Tempest Therapeutics Inc.
    $TPST
    1/22/2026$11.00Neutral → Buy
    H.C. Wainwright
    Relay Therapeutics Inc.
    $RLAY
    12/12/2025$13.00Equal Weight → Overweight
    Wells Fargo
    Relay Therapeutics Inc.
    $RLAY
    9/4/2025$15.00Buy
    Guggenheim
    Relay Therapeutics Inc.
    $RLAY
    4/17/2025$4.00Equal Weight
    Wells Fargo
    Tempest Therapeutics Inc.
    $TPST
    4/10/2025Sector Outperform → Sector Perform
    Scotiabank
    Tempest Therapeutics Inc.
    $TPST
    4/10/2025Buy → Neutral
    H.C. Wainwright
    Cassava Sciences Inc.
    $SAVA
    11/26/2024Buy → Neutral
    H.C. Wainwright
    More analyst ratings

    $BLPH
    $BPTH
    $BYSI
    $CMRA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 3 filed by Scinai Immunotherapeutics Ltd.

    3 - Scinai Immunotherapeutics Ltd. (0001611747) (Issuer)

    3/18/26 10:08:31 AM ET
    $SCNI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 3 filed by Scinai Immunotherapeutics Ltd.

    3 - Scinai Immunotherapeutics Ltd. (0001611747) (Issuer)

    3/18/26 10:06:28 AM ET
    $SCNI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 3 filed by Scinai Immunotherapeutics Ltd.

    3 - Scinai Immunotherapeutics Ltd. (0001611747) (Issuer)

    3/18/26 10:05:12 AM ET
    $SCNI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $BLPH
    $BPTH
    $BYSI
    $CMRA
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    President and CEO Dow Geoffrey S bought $7,759 worth of shares (9,670 units at $0.80), increasing direct ownership by 19% to 59,618 units (SEC Form 4)

    4 - 60 DEGREES PHARMACEUTICALS, INC. (0001946563) (Issuer)

    12/16/25 5:41:35 PM ET
    $SXTP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    President and CEO Dow Geoffrey S bought $12,204 worth of shares (12,963 units at $0.94), increasing direct ownership by 35% to 49,948 units (SEC Form 4)

    4 - 60 DEGREES PHARMACEUTICALS, INC. (0001946563) (Issuer)

    12/12/25 8:39:45 AM ET
    $SXTP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Anderson Robert Eugene Jr bought $24,940 worth of shares (8,600 units at $2.90) (SEC Form 4)

    4 - CASSAVA SCIENCES INC (0001069530) (Issuer)

    11/25/25 4:06:25 PM ET
    $SAVA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BLPH
    $BPTH
    $BYSI
    $CMRA
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Scinai Immunotherapeutics Highlights Expanded CDMO Platform and Immunology Pipeline at BIO-Europe Spring® 2026

    JERUSALEM, March 19, 2026 /PRNewswire/ -- Scinai Immunotherapeutics Ltd. (NASDAQ:SCNI), a biopharmaceutical company advancing a pipeline of innovative inflammation and immunology therapeutics, and the owner of Scinai Biopharma Services Ltd., a rapidly expanding contract development and manufacturing organization (CDMO) serving biotechnology and pharmaceutical companies, today announced its participation in BIO-Europe Spring® 2026, taking place March 23–25 in Lisbon, Portugal. This will be Scinai's first major international conference following its recent acquisition of Recipharm Israel and strategic collaboration with Recipharm, marking a significant expansion of its development and manufact

    3/19/26 7:50:00 AM ET
    $SCNI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    60 Degrees Pharmaceuticals Files New Dietary Ingredient Notification (NDIN) with FDA for Australian Chestnut Extract

    FDA has until May 25, 2026 to object to the notification, after which the Company will be free to market its proposed dietary supplement containing Australian Chestnut ExtractCompany has signed an option agreement with Florida State University (FSU) to license a capsule formulation, expanding on its recent exercise of a license option for large-scale production WASHINGTON, March 18, 2026 (GLOBE NEWSWIRE) -- 60 Degrees Pharmaceuticals, Inc. (NASDAQ:SXTP, SXTPW)) ("60 Degrees Pharma" or the "Company"), a pharmaceutical company focused on developing new medicines for vector-borne disease, today announced it submitted a New Dietary Ingredient Notification (NDIN) to the U.S. Food and Drug Admi

    3/18/26 8:01:00 AM ET
    $SXTP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Scinai Immunotherapeutics Receives Nasdaq Notification Regarding Minimum Bid Price

    JERUSALEM, March 16, 2026 /PRNewswire/ -- Scinai Immunotherapeutics Ltd. (NASDAQ:SCNI) ("Scinai" or the "Company"), today announced that it received a written notification from the Nasdaq Listing Qualifications Department on March 12, 2026 indicating that the Company is not in compliance with the Nasdaq Capital Market's minimum bid price requirement under Nasdaq Listing Rule 5550(a)(2), because the closing bid price of the American Depositary Shares ("ADSs") was below $1.00 per share for 30 consecutive business days. The notification has no immediate effect on the listing or trading of the ADSs on the Nasdaq Capital Market.In accordance with Nasdaq Listing Rule 5810(c)(3)(A), the Company has

    3/16/26 4:05:00 PM ET
    $SCNI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $BLPH
    $BPTH
    $BYSI
    $CMRA
    SEC Filings

    View All

    SEC Form 6-K filed by Scinai Immunotherapeutics Ltd.

    6-K - Scinai Immunotherapeutics Ltd. (0001611747) (Filer)

    3/19/26 10:08:08 AM ET
    $SCNI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Relay Therapeutics Inc. filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits

    8-K - Relay Therapeutics, Inc. (0001812364) (Filer)

    3/16/26 8:30:08 AM ET
    $RLAY
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 424B5 filed by 60 Degrees Pharmaceuticals Inc.

    424B5 - 60 DEGREES PHARMACEUTICALS, INC. (0001946563) (Filer)

    3/13/26 5:17:36 PM ET
    $SXTP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BLPH
    $BPTH
    $BYSI
    $CMRA
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Relay Therapeutics upgraded by Oppenheimer with a new price target

    Oppenheimer upgraded Relay Therapeutics from Perform to Outperform and set a new price target of $14.00

    1/26/26 8:32:07 AM ET
    $RLAY
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Tempest Therapeutics upgraded by H.C. Wainwright with a new price target

    H.C. Wainwright upgraded Tempest Therapeutics from Neutral to Buy and set a new price target of $11.00

    1/22/26 8:24:05 AM ET
    $TPST
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Relay Therapeutics upgraded by Wells Fargo with a new price target

    Wells Fargo upgraded Relay Therapeutics from Equal Weight to Overweight and set a new price target of $13.00

    12/12/25 8:37:26 AM ET
    $RLAY
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $BLPH
    $BPTH
    $BYSI
    $CMRA
    Leadership Updates

    Live Leadership Updates

    View All

    Outset Medical Reports Unaudited Fourth Quarter and 2025 Results

    SAN JOSE, Jan. 12, 2026 (GLOBE NEWSWIRE) -- Outset Medical, Inc. (NASDAQ:OM), a medical technology company pioneering a first-of-its-kind technology to reduce the cost and complexity of dialysis, today reported unaudited revenue for the fourth quarter and fiscal year ended December 31, 2025, and named Karen N. Prange to its board of directors. Unaudited Fourth Quarter and 2025 Results Revenue in the fourth quarter totaled approximately $28.9 million, bringing revenue for 2025 to approximately $119.5 million, a 5% increase over $113.7 million in 2024.Exiting 2025, more than 1,000 sites of care have insourced dialysis with Outset, performing roughly 1 million treatments per year and more t

    1/12/26 8:30:00 AM ET
    $OM
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Cassava Reports Q3 2025 Financials Results and Provides Business Update

    Simufilam advancing towards a clinical study expected to begin in H1 2026 for the potential treatment of TSC-related epilepsyFurther fortified our strategic capabilities with the appointment of Dawn C. Bir to the Board of Directors$106.1 million in cash and cash equivalents at September 30, 2025. Expected to support operations into 2027 AUSTIN, Texas, Nov. 12, 2025 (GLOBE NEWSWIRE) -- – Cassava Sciences, Inc. (NASDAQ:SAVA, "Cassava", the "Company")), a biotechnology company focused on developing novel, investigational treatments for central nervous system (CNS) disorders such as Tuberous Sclerosis Complex (TSC)-related epilepsy, today reported financial results for the third quarter ende

    11/12/25 8:00:00 AM ET
    $SAVA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Cassava Sciences Appoints Dawn C. Bir to the Board of Directors

    AUSTIN, Texas, Oct. 22, 2025 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (NASDAQ:SAVA, "Cassava", the "Company")), a biotechnology company focused on developing novel, investigational treatments for central nervous system (CNS) disorders such as Tuberous Sclerosis Complex (TSC)-related epilepsy, today announced the appointment of Ms. Dawn C. Bir to its Board of Directors (the Board). Dawn Bir is a seasoned biopharmaceutical executive and board member with a track record of contributing to the successful development and value creation for pre-commercial and commercial biotechnology and life science companies including Reata Pharmaceuticals, Inc. (acquired by Biogen Inc.), Geron Corporation,

    10/22/25 8:00:00 AM ET
    $SAVA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BLPH
    $BPTH
    $BYSI
    $CMRA
    Financials

    Live finance-specific insights

    View All

    Outset Medical to Report Fourth Quarter 2025 Financial Results on Wednesday, February 11, 2026

    SAN JOSE, Calif., Jan. 26, 2026 (GLOBE NEWSWIRE) -- Outset Medical, Inc. (NASDAQ:OM) ("Outset"), a medical technology company pioneering a first-of-its-kind technology to reduce the cost and complexity of dialysis, today announced that it will release financial results for the fourth quarter and full-year 2025 after the close of trading on Wednesday, February 11, 2026. On the same day, at 1:30 p.m. Pacific time (4:30 p.m. Eastern time), Leslie Trigg, Chair and Chief Executive Officer, and Renee Gaeta, Chief Financial Officer, will host a conference call to discuss financial and operating results. Conference Call DetailsThe conference call will begin at 1:30 p.m. Pacific time (4:30 p.m. E

    1/26/26 4:05:00 PM ET
    $OM
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Tempest Announces Record Date for Anticipated Dividend Distribution of Warrants to Stockholders

    BRISBANE, Calif., Jan. 20, 2026 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (NASDAQ:TPST) ("Tempest"), a clinical-stage biotechnology company with a pipeline of targeted and immune-mediated therapeutics to fight cancer, today announced the record date of January 30, 2026 (the "Record Date") for the distribution of warrants to purchase Tempest common stock ("Warrants") as a dividend (the "Warrant Dividends"), as contemplated by Tempest's previously announced Asset Purchase Agreement (the "Asset Purchase Agreement") with Erigen LLC and Factor Bioscience Inc. The distribution of the Warrant Dividends is expected to be Tuesday, February 3, 2026, but is subject to the prior satisfaction of c

    1/20/26 5:20:02 PM ET
    $TPST
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Outset Medical to Report Third Quarter 2025 Financial Results on Monday, November 10, 2025

    SAN JOSE, Calif., Oct. 27, 2025 (GLOBE NEWSWIRE) -- Outset Medical, Inc. (NASDAQ:OM) ("Outset"), a medical technology company pioneering a first-of-its-kind technology to reduce the cost and complexity of dialysis, today announced that it will release financial results for the third quarter 2025 after the close of trading on Monday, November 10, 2025. On the same day, at 1:30 p.m. Pacific time (4:30 p.m. Eastern time), Leslie Trigg, Chair and Chief Executive Officer, and Renee Gaeta, Chief Financial Officer, will host a conference call to discuss financial and operating results. Conference Call DetailsThe conference call will begin at 1:30 p.m. Pacific time (4:30 p.m. Eastern time) on Mo

    10/27/25 4:05:00 PM ET
    $OM
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $BLPH
    $BPTH
    $BYSI
    $CMRA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by BeyondSpring Inc.

    SC 13G/A - BeyondSpring Inc. (0001677940) (Subject)

    11/14/24 9:52:50 PM ET
    $BYSI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Scinai Immunotherapeutics Ltd.

    SC 13G/A - Scinai Immunotherapeutics Ltd. (0001611747) (Subject)

    11/14/24 4:28:57 PM ET
    $SCNI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form SC 13G filed by T2 Biosystems Inc.

    SC 13G - T2 Biosystems, Inc. (0001492674) (Subject)

    11/14/24 3:38:45 PM ET
    $TTOO
    Medical/Dental Instruments
    Health Care